NEWCELX LTD Stock Price, News & Analysis

NLS Pharmaceutics Ltd. (NASDAQ: NLSP, NLSPW) announces CEO Alex Zwyer will hold one-on-one meetings at the 2022 BIO CEO & Investor Conference. The company focuses on innovative therapies for rare CNS disorders, with its lead product candidate, Quilience, an extended-release formulation of mazindol, targeting narcolepsy. NLS has received Orphan Drug Designations for Quilience in both the U.S. and Europe. A Phase 2a clinical trial for Quilience is ongoing, following a successful Phase 2 study for its ADHD treatment, Nolazol.

NLS Pharmaceutics Ltd. (NASDAQ: NLSP, NLSPW) has successfully achieved its enrollment target for a Phase 2a clinical trial, with over 50% of participants enrolled. The trial, which focuses on Quilience® (Mazindol ER) for narcolepsy treatment, includes 21 clinical sites across the U.S. Notably, nearly 90% of patients have opted into an Open Label Extension study. Interim data will be presented at the World Sleep Congress in Rome, Italy, from March 11-16, 2022, detailing safety, efficacy, and patient outcomes as the company aims to finalize enrollment by Q2 2022.

NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) has announced its participation in the upcoming International Narcolepsy Webinar hosted by Wake Up Narcolepsy on January 20-21, 2022. The webinar aims to educate patients and caregivers about narcolepsy treatments and features a presentation on mazindol, NLS's potential treatment under study in a phase 2 trial. Interested participants can join the event online. Quilience (mazindol ER) has received Orphan Drug Designations in the U.S. and Europe for narcolepsy treatment.

NLS Pharmaceutics Ltd. announces the grant of U.S. Patent No. 11207271 for its lead product candidate, Quilience® (mazindol ER), effective January 4, 2022. This patent covers the use of Quilience® for treating ADHD and narcolepsy, bolstering NLS's intellectual property in key markets including the U.S., Europe, Canada, and South Korea. The company anticipates reporting Phase 2a results for Quilience® in treating narcolepsy in the first quarter of 2022, emphasizing the drug's potential to address significant unmet medical needs.

NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) has released final results from a preclinical study on NLS-4 (Lauflumide), highlighting its potential as a treatment for chronic fatigue associated with Long-Covid. The study indicates that NLS-4 significantly outperformed modafinil in improving circadian rhythm and chronic fatigue syndrome in animal models, at doses four times lower than modafinil. Notably, NLS-4 did not induce weight loss or hepatic toxicity. The company aims to advance NLS-4's development amidst rising demand for effective treatments for Long-Covid fatigue.

NLS Pharmaceutics Ltd. (NASDAQ: NLSP, NLSPW) provides updates in a letter to shareholders from CEO Alex Zwyer, highlighting significant progress in clinical development for Quilience, an innovative narcolepsy treatment. Key achievements include entering Phase 2 clinical trials, successful patent applications in the U.S., Europe, and Canada, and positive pre-clinical data on NLS-4 for chronic fatigue syndrome. The company anticipates reporting interim results from the POLARIS trial in Q1 2022, and plans to explore additional market opportunities for Quilience beyond narcolepsy.

NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) has announced promising preclinical data for its next-generation drug candidate, NLS-4 (Lauflumide), targeting chronic fatigue associated with Long-COVID. In a study, rats treated with NLS-4 exhibited improved nighttime activity and greater motor-stimulating behavior compared to those treated with modafinil. The results suggest NLS-4 may effectively combat symptoms of fatigue and sleep disturbances related to COVID-19. The company is committed to advancing NLS-4 into clinical development to alleviate chronic fatigue in Long-COVID patients.

NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW), a Swiss clinical-stage pharmaceutical company, is set to present at The Micro Cap Rodeo Fall Harvest Conference from October 5-8, 2021. CEO Alex Zwyer will provide a corporate overview on October 5 at 9:00 am ET. The presentation is accessible through a provided link, and a replay will be available on the company's website. NLS's lead candidate, Quilience, is in phase 2 studies for narcolepsy treatment and has received Orphan Drug Designations in the U.S. and Europe.

NLS Pharmaceutics Ltd. (NASDAQ: NLSP, NLSPW) announced a $20 million Standby Equity Distribution Agreement (SEDA) with YA II PN, Ltd., allowing the company to issue common shares over 36 months at an 8% discount. A $2.5 million immediate investment at $1.90 per share is also included. Proceeds will be used for advancing pipeline assets and general working capital. Quilience®, the company's lead product, is in Phase 2 trials for narcolepsy. The shares will only be sold following SEC registration. Risks include potential clinical trial delays and market acceptance issues.